Ionis Pharmaceuticals Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Good afternoon. Thanks for joining us. I'm Salveen Richter, biotechnology analyst at Goldman Sachs, and we're pleased to have Ionis with us. And with us from Ionis is Brett Monia, CEO of the company. Brett, thank you for being here this morning -- this afternoon.
Questions & Answers
To start, could you walk us through the outlook for the remainder of 2021 in terms of key events and data catalysts for the company?
Sure thing, Salveen, and thanks for the invitation. It's a pleasure to be here today. Yes, quite a number of news coming out of Ionis projected for the second half of the year. Data readouts and as well as new study starts.
Of course, the most exciting data readout that we're really looking forward to is the Phase III readout for tofersen in SOD1-ALS. This is a readout
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |